MBOAT7 rs641738 variant in metabolic-dysfunction-associated fatty liver disease and cardiovascular risk
- PMID: 36818318
- PMCID: PMC9924805
- DOI: 10.15386/mpr-2504
MBOAT7 rs641738 variant in metabolic-dysfunction-associated fatty liver disease and cardiovascular risk
Abstract
Introduction: Although metabolic-dysfunction-associated fatty liver disease (MAFLD) is associated with an increased cardiovascular risk, MAFLD predisposing genetic variants were not steadily related to cardiovascular events. Therefore, we aimed to assess whether membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) rs641738 variant is associated with an increased cardiovascular risk in in MAFLD patients.
Methods: We conducted an observational cross-sectional study including 77 subjects (38 MAFLD patients, 39 controls), between January-September 2020 using hepatic ultrasonography and SteatoTestTM to assess hepatic steatosis. Echocardiographic and Doppler ultrasound parameters were evaluated. Genomic DNA was extracted and rs641738 SNP was genotyped using TaqMan assays.
Results: The rs641738 variant was not significantly associated with MAFLD, with a p-value of 0.803, 0.5265, 0.9535, and 0.5751 for codominant, dominant, recessive, and overdominant genotypes, respectively. The rs641738 variant overdominant genotype significantly predicted atherosclerotic cardiovascular disease (ASCVD) risk algorithm in univariate analysis (-4.3 [95% CI -8.55 - -0.55, p-value= 0.048]), but lost significance after multivariate analysis (-3.98 [95% CI -7.9 - -0.05, p-value= 0.053]). The rs641738 variant recessive genotype significantly predicted ActiTest in univariate analysis (0.0963 [95% CI 0.0244 - 0.1681, p-value= 0.009]), but lost significance after multivariate analysis (0.0828 [95% CI -0.016 - 0.1816, p-value= 0.105]).
Conclusion: No significant association was observed between rs641738 variant and MAFLD in the studied population. The rs641738 variant was found to predict ASCVD risk score and ActiTest in univariate linear regression analysis. However, the significance of both associations was lost after performing multivariate analysis.
Keywords: MBOAT7; cardiovascular disease; genes; hepatic steatosis; metabolic associated fatty liver disease (MAFLD); rs641738.
Similar articles
-
Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review.Eur J Clin Invest. 2020 Oct;50(10):e13331. doi: 10.1111/eci.13331. Epub 2020 Jul 13. Eur J Clin Invest. 2020. PMID: 32589269
-
Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.Liver Int. 2018 Jul;38(7):1300-1307. doi: 10.1111/liv.13689. Epub 2018 Jan 24. Liver Int. 2018. PMID: 29314568
-
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.Gastroenterology. 2016 May;150(5):1219-1230.e6. doi: 10.1053/j.gastro.2016.01.032. Epub 2016 Feb 2. Gastroenterology. 2016. PMID: 26850495 Free PMC article.
-
Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk.J Clin Med. 2022 Apr 28;11(9):2488. doi: 10.3390/jcm11092488. J Clin Med. 2022. PMID: 35566616 Free PMC article.
-
MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD.EBioMedicine. 2020 Jul;57:102866. doi: 10.1016/j.ebiom.2020.102866. Epub 2020 Jul 3. EBioMedicine. 2020. PMID: 32629394 Free PMC article. Review.
Cited by
-
Phospholipid Acyltransferases: Characterization and Involvement of the Enzymes in Metabolic and Cancer Diseases.Cancers (Basel). 2024 May 31;16(11):2115. doi: 10.3390/cancers16112115. Cancers (Basel). 2024. PMID: 38893234 Free PMC article. Review.
References
-
- Eslam M, Sanyal AJ, George J International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158:1999–2014e1. - PubMed
-
- Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–209. - PubMed
-
- Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018;68:268–279. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous